Skip to main content
Clinical Trials/NCT05118399
NCT05118399
Completed
Phase 4

Addition of Liposomal Bupivacaine to Standard Bupivacaine Versus Standard Bupivacaine Alone in the Supraclavicular Brachial Plexus Block: a Randomized Controlled Trial

The University of Hong Kong1 site in 1 country80 target enrollmentNovember 15, 2021

Overview

Phase
Phase 4
Intervention
Bupivacaine Injection [Marcaine]
Conditions
Acute Pain
Sponsor
The University of Hong Kong
Enrollment
80
Locations
1
Primary Endpoint
postoperative AUC pain score at rest
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Brachial plexus blocks (BPB) are commonly used to provide regional anaesthesia for patients undergoing distal radial fracture surgery. Distal radial (DR) fracture surgery is a commonly performed orthopaedic surgery, and is usually associated with moderate postoperative pain. Poor postoperative pain control can impair rehabilitation, delay recovery and negatively impact outcomes after surgery. Liposomal bupivacaine (EXPAREL) is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine. Liposomal bupivacaine can provide longer analgesia for up to 72 hours, and may therefore achieve greater analgesic efficacy compared to non-liposomal long-acting local anaesthetics. A number of clinical trials have studied the effect liposomal bupivacaine given as local infiltration. However, there is little evidence on liposomal bupivacaine for regional nerve blocks, and the use of liposomal bupivacaine for supraclavicular brachial plexus block - which is used for regional anaesthesia for distal radial fracture surgery - have not been studied before. This project is a randomized controlled trial to determine whether adding liposomal bupivacaine to long-acting local anaesthetics for supraclavicular BPB will improve and prolong postoperative analgesia in patients undergoing distal radial fracture surgery. Longer term secondary outcomes would be accessed including upper limb functional scores, chronic pain, and health related quality of life.

Registry
clinicaltrials.gov
Start Date
November 15, 2021
End Date
March 8, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Wong Sau Ching Stanley

Clinical Assistant Professor

The University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiologist (ASA) status I-III
  • Age 18-90 years old
  • Scheduled for distal radial fracture fixation (Open reduction and internal fixation with volar approaching locking plate)
  • Patients with informed consent to participate in the study

Exclusion Criteria

  • Ulnar shaft/ neck physis fracture
  • Revision surgery
  • Previous fractures or surgery in the affected distal radius
  • Surgery involving more than the affected arm
  • Higher energy and high-grade fracture cases - road traffic accident, fall from height, open fractures, combined distal radius and distal ulna fractures, fractures requiring external fixation, fractures with severe articular comminution or severe metaphyseal extension, comminuted fractures requiring more than a single volar approach incision and a single volar locking plate implant
  • Cases with painful conditions affecting the upper limb prior to surgery such as cervical spine, shoulder, elbow, other hand and wrist problems
  • Cases with baseline (pre-injury) QuickDASH score worse than 10 out of 100
  • Respiratory compromise (requires long term oxygen)
  • History of seizures
  • Pre-existing neurological disorder/deficit

Arms & Interventions

To receive supraclavicular BPB using standard ropivacaine only.

20ml of plain bupivacaine will be injected using 2 syringes, so 10ml of 0.5% plain bupivacaine will be injected, and immediately followed by another 10ml of 0.5% plain bupivacaine.

Intervention: Bupivacaine Injection [Marcaine]

To receive supraclavicular BPB using liposomal bupivacaine together with ropivacaine.

10ml of 0.5% plain bupivacaine will be injected, and immediately followed by 10ml of 1.33% liposomal bupivacaine.

Intervention: Bupivacaine Liposome 13.3 MG/ML [Exparel]

Outcomes

Primary Outcomes

postoperative AUC pain score at rest

Time Frame: First 48 hours after surgery

Pain severity would be rated at rest after surgery using numerical rating scale with 0 to 10 where 0=no pain and 10=the worst possible pain

Study Sites (1)

Loading locations...

Similar Trials